Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis
PHASE3CompletedINTERVENTIONAL
Enrollment
200
Participants
Timeline
Start Date
December 31, 1995
Conditions
Systemic SclerosisRaynaud Disease
Interventions
DRUG
iloprost
All Listed Sponsors
collaborator
University of Pittsburgh
OTHER
lead
National Center for Research Resources (NCRR)
NIH
NCT00004786 - Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis | Biotech Hunter | Biotech Hunter